Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor

[Image: see text] Boceprevir (SCH 503034), 1, a novel HCV NS3 serine protease inhibitor discovered in our laboratories, is currently undergoing phase III clinical trials. Detailed investigations toward a second generation protease inhibitor culminated in the discovery of narlaprevir (SCH 900518), 37...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Arasappan, Ashok, Bennett, Frank, Bogen, Stephane L., Venkatraman, Srikanth, Blackman, Melissa, Chen, Kevin X., Hendrata, Siska, Huang, Yuhua, Huelgas, Regina M., Nair, Latha, Padilla, Angela I., Pan, Weidong, Pike, Russell, Pinto, Patrick, Ruan, Sumei, Sannigrahi, Mousumi, Velazquez, Francisco, Vibulbhan, Bancha, Wu, Wanli, Yang, Weiying, Saksena, Anil K., Girijavallabhan, Viyyoor, Shih, Neng-Yang, Kong, Jianshe, Meng, Tao, Jin, Yan, Wong, Jesse, McNamara, Paul, Prongay, Andrew, Madison, Vincent, Piwinski, John J., Cheng, Kuo-Chi, Morrison, Richard, Malcolm, Bruce, Tong, Xiao, Ralston, Robert, Njoroge, F. George
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Chemical Society 2010
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4007962/
https://ncbi.nlm.nih.gov/pubmed/24900178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml9000276
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk